.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Argus Health
Dow
QuintilesIMS
Cerilliant
McKinsey
Teva
Chubb
Daiichi Sankyo
US Department of Justice

Generated: September 20, 2017

DrugPatentWatch Database Preview

Hydrocodone bitartrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for hydrocodone bitartrate and what is the scope of hydrocodone bitartrate patent protection?

Hydrocodone bitartrate
is the generic ingredient in nine branded drugs marketed by Purdue Pharma Lp, Teva Branded Pharm, Pernix Ireland Pain, Actavis Labs Fl Inc, Abbvie, Teva, Vintage Pharms, Sun Pharm Inds Inc, Amneal Pharms Ny, Aurolife Pharma Llc, Alpharma Us Pharms, Tris Pharma Inc, Cypress Pharm, Mayne Pharma Inc, and Paddock Llc, and is included in seventeen NDAs. There are forty-nine patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Hydrocodone bitartrate has six hundred and six patent family members in fifty-one countries.

There are twenty-two drug master file entries for hydrocodone bitartrate. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: hydrocodone bitartrate

Tradenames:9
Patents:49
Applicants:15
NDAs:17
Drug Master File Entries: see list22
Suppliers / Packagers: see list3
Bulk Api Vendors: see list10
Clinical Trials: see list112
Patent Applications: see list54
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:hydrocodone bitartrate at DailyMed

Pharmacology for Ingredient: hydrocodone bitartrate

Drug ClassOpioid Agonist
Mechanism of ActionOpioid Agonists

Tentative approvals for HYDROCODONE BITARTRATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe10MGCAPSULE, EXTENDED RELEASE; ORAL
► Subscribe► Subscribe40MGCAPSULE, EXTENDED RELEASE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm
VANTRELA ER
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL207975-005Jan 17, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Pernix Ireland Pain
ZOHYDRO ER
hydrocodone bitartrate
CAPSULE, EXTENDED RELEASE;ORAL202880-004Oct 25, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-006Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Pernix Ireland Pain
ZOHYDRO ER
hydrocodone bitartrate
CAPSULE, EXTENDED RELEASE;ORAL202880-002Oct 25, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Teva Branded Pharm
VANTRELA ER
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL207975-001Jan 17, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-006Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Amneal Pharms Ny
HYDROCODONE BITARTRATE AND IBUPROFEN
hydrocodone bitartrate; ibuprofen
TABLET;ORAL076642-002Mar 18, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Branded Pharm
VANTRELA ER
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL207975-003Jan 17, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-003Nov 20, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Vintage Pharms
HYDROCODONE BITARTRATE AND IBUPROFEN
hydrocodone bitartrate; ibuprofen
TABLET;ORAL077723-001Nov 6, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: hydrocodone bitartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-003Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-001Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-002Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-007Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-006Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-004Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-005Nov 20, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: hydrocodone bitartrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,337,888Pharmaceutical formulation containing gelling agent► Subscribe
8,652,497Pharmaceutical formulation containing irritant► Subscribe
6,730,325 Multiparticulate modified release composition► Subscribe
7,157,103Pharmaceutical formulation containing irritant► Subscribe
7,141,250Pharmaceutical formulation containing bittering agent► Subscribe
7,842,307Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent► Subscribe
7,514,100Controlled release hydrocodone formulations► Subscribe
8,524,275Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent► Subscribe
8,114,384Process for the production of an abuse-proofed solid dosage form► Subscribe
8,951,555Controlled release hydrocodone formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: hydrocodone bitartrate

Country Document Number Estimated Expiration
Japan6042387► Subscribe
MexicoPA06001452► Subscribe
Peru08142005► Subscribe
European Patent Office2826469► Subscribe
World Intellectual Property Organization (WIPO)03013476► Subscribe
New Zealand613079► Subscribe
China105267170► Subscribe
World Intellectual Property Organization (WIPO)2007027273► Subscribe
Austria499101► Subscribe
European Patent Office1014941► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
McKinsey
Johnson and Johnson
Mallinckrodt
Cerilliant
Novartis
Deloitte
QuintilesIMS
Farmers Insurance
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot